As a global pharmaceutical company with a biotech mindset and a proven ability to provide new, life-changing therapies, Ipsen is a leading player in its core therapeutic areas.

Q1 2021 sales update: conference call and webcast


Date:            Thursday, 22 April 2021
Time:            Conference call and webcast – 2:30pm CEST / 8:30 EST
Click here to register
Conference ID: 2495337
Click here to access the press release

Q1 2021 sales update

2020 Capital Markets Day

Capital Markets Day

2020 Universal Registration Document

This registration document contains forward-looking statements about the Group’s targets and forecasts, including the Annual Financial Report. The registration document provides a comprehensive information about our company, its activities, financial information, HR, and legal information.



2020 half year financial report








Useful documents

Research & Development pipeline

Ipsen R&D has a valuable pipeline encompassing both lifecycle management of our well-established products, and the development of innovative new molecules.

Learn more

We are focused on accelerating our sales growth while improving our profitability and cash flow generation, in order to further invest in business development to build an innovative and sustainable pipeline and to maintain the growth momentum of the business.

Aymeric Le Chatelier, CFO

Investor Relations Contacts

Craig Marks
Vice President, Investor Relations
+44 (0) 7584 349 193

Adrien Dupin de Saint-Cyr
Investor Relations Manager
+33 (0) 6 64 26 17 49


Contact us

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved. - 2021